BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Policy

  Where We Are: Omicron BA.2 Persists while Vaccines Lower Risk of Long COVID

  U.K. researchers found that the first dose of any vaccine was linked with an initial 12.8% decrease in the odds of Long COVID.

  May 19, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Policy

  Life Sciences Companies Shore Up Resources as US Confirms First Monkeypox Case

  On Wednesday evening, a man in Massachusetts became the first person reported to have a case of monkeypox in the U.S. The man contracted monkeypox after traveling to Canada.

  May 19, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Business

  BioSpace Movers & Shakers: Jeffrey Leiden, Don Hayden, Zentalis, Entera and More

  Life sciences organizations and companies strengthen their leadership teams and boards with these Movers & Shakers.

  May 19, 2022

   · 

  8 min read

   · 

  Alex Keown
• 

  Business

  Pfizer, Headlands Research Partner to Bring Trials to Highly Diverse Areas

  Pfizer with Headlands Research plans to launch new clinical trial sites in areas that have highly diverse populations.

  May 19, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  Collaborative Analysis Reveals “Class Effect” in DMD Safety Issues

  Pfizer, Sarepta Therapeutics, Genethon and Solid Biosciences are working on gene therapies for Duchenne Muscular Dystrophy. Now, the four companies have teamed up.

  May 19, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Mersana Enters Busy Gastric Cancer Space with Orphan Drug Designation

  On Thursday, Mersana announced that the FDA granted an orphan drug designation to one of its lead assets, XMT-2056, which is intended to treat gastric cancer.

  May 19, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Career Advice

  Intellia Weighs in on How to Identify and Avoid Scam Job Offers

  BioSpace sat down with Maritza Gamboa, the associate director of talent acquisition at Intellia Therapeutics, to find out how to identify and avoid scam job offers.

  May 19, 2022

   · 

  4 min read

   · 

  Rosemary Scott
• 

  Drug Development

  Enanta’s Phase II Failure Highlights Challenges in RSV Space

  Enanta Pharmaceuticals’ attempt to find an effective treatment for respiratory syncytial virus (RSV) met a roadblock after its candidate failed to meet the primary endpoint in Phase II.

  May 19, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Research Roundup: New Hope for T1 Diabetes Pancreatic Cell Transplants

  Pancreatic transplants are difficult to pull off for Type 1 diabetes, but new technology may make it possible, and infusions of spinal fluid from young mice to older ones reportedly reverses memory loss.

  May 19, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  Janssen Presents New Data that could Set Anti-Inflammatory Drug Tremfya Apart

  Janssen’s Tremfya, an IL-23 inhibitor, is showing an ability to separate itself from AbbVie’s Skyrizi in preventing the activation of cells that drive inflammation.

  May 19, 2022

   · 

  2 min read

   · 

  Alex Keown